Daniel Mutisya Email & Phone Number

United States

•I successfully Co-led R&D efforts to design & develop novel ligands including GalNAc, Peptides & Lipids for targeted delivery of drug agents to various tissues.•Designed innovative chemical bioconjugation strategies to link the targeting ligands to RNA oligonucleotides and antibodies.•I Successfully directed efforts towards designing and synthesis of oligonucleotides and their conjugation to the targeting ligands, purification, and characterization of the ligand-RNA constructs.

United States

• Developed and optimized protocols for synthesis of chemically modified oligonucleotides using custom solid phase synthesis.•successfully designed and developed novel Peptide GalNAc based ligands for targeted delivery of therapeutic siRNAs to the liver.•Successfully designed and developed Bioconjugation strategies of Oligos and targeting ligands.•Developed bioconjugation protocols for oligos and Antibodies.•Synthesized modified short interfering RNAs (siRNAs) using ABI and Mermade 12 DNA/RNA synthesizers. •Performed process development aimed at scale up synthesis of siRNAs on Mermade 12 & AKTA OP100.• Developed new SOPs for synthesis, processing, and analysis of our novel ligand-siRNA conjugates.• Developed chromatographic methods for purification of our modified RNA oligonucleotides using IEX & RP HPLC, TFF desalting and Solid phase extraction techniques. • Developed qualitative and quantitative techniques of analysis of our products using Liquid Chromatography–Mass Spectrometry (LC-MS), Ion-Exchange (IEX), and Reversed Phase (RP)-HPLC, 1D & 2D NMR, FT-IR, UV/VIS, DSC, KF, DLS and CE

Ga Usa

Teaching General and Organic chemistry courses to undergraduate students

Sc. Usa

Preparation and delivery of undergraduate level course in the areas of Organic Chemistry and General Chemistry.

Ny. Usa

Designing and developing of novel RNA chemical modifications aimed at improving therapeutic properties of the modified siRNA agents.